Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Those for whom Mavyret did not work the first time had a high cure rate with this intensified retreatment regimen.
Human rights activist Philip Baldwin writes about his experiences living with hepatitis C and HIV, and his treatment for hep C.
Hepatitis C advocate Peter McLoyd transformed his bad times into good ones.
The real-world cure rates offered by Sovaldi (sofosbuvir)-based hep C virus regimens have not been as good as those seen in clinical trials
The U.S. Food and Drug Administration has approved AbbVie’s Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with...
Twelve or 18 weeks of Merck’s grazoprevir/elbasvir, with or without ribavirin, cured 91 to 100 percent of hard-to-treat people with genotype 1...
Gilead Sciences’ Sovaldi (sofosbuvir) and ribavirin cured high rates of people coinfected with HIV and hepatitis C virus (HCV).
Sovaldi (sofosbuvir) and ribavirin cured between 84 percent and 91 percent of people coinfected with HIV and genotypes 1 through 4 of hepatiti...
The FDA approved Sovaldi among people coinfected with hep C and HIV.
Sovaldi and ribavirin cured 75 percent of those with genotype 1 of hepatitis C in a recent trial
With the FDA approval of Sovaldi (sofosbuvir) and Olysio (simeprevir), many people with hepatitis C, including those coinfected with HIV...
The FDA has approved Sovaldi (sofosbuvir), a once-daily oral nucleotide analog polymerase inhibitor to treat people with hepatitis C.
Incivek added to interferon and ribavirin shortens the treatment duration and raises cure rates among gay, HIV-positive men with acute hep C
Victrelis, when added to interferon and ribavirin, improves cure rates of hepatitis C and does not raise major treatment risks in those coinfe...
Researchers reveled in promising new data on forthcoming hepatitis C therapies.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.